Abstract After acquiring a varicella virus infection, the virus can reactivate and cause herpes zoster (HZ)-a painful skin rash. A complication of HZ is long-term persistence of pain after the rash has resolved (so-called postherpetic neuralgia, PHN). We aimed to describe the epidemiology of HZ/PHN and to estimate HZ/PHN-related costs in the German statutory health insurance (SHI) system (*85 % of the total population). Treatment data of one large SHI was utilized, containing data on approximately 240,000 insured and their utilisation of services in [2004][2005][2006][2007][2008][2009]. Identification of HZ-and PHN-cases was performed based on 'International Statistical Classification of Diseases' and specific medications using a control-group design. Incidences per 1,000 person-years (PY) and cost-of-illness for 1 year following HZ-onset considering the payer and societal perspective were calculated. All amounts were inflated to 2010 Euros. Population-figures were standardised and extrapolated to the total SHI-population in Germany in 2010. A mean annual incidence of 5.79 HZ-cases per 1,000 PY was observed, translating into an estimated 403,625 HZ-cases per year in the total SHI-population. Approximately 5 % of HZ-cases developed PHN. One HZ-case caused on average €210 and €376 of costs from the payer and societal perspective, respectively. The development of PHN generated additional costs of €1,123 (€1,645 societal perspective). Total annual HZ/PHN-related costs were estimated at €182 million (€105 million) to society (payer). HZ and PHN place a considerable burden on the German SHI-system. Since HZ-vaccines will soon be available, a healtheconomic evaluation of these vaccines should be conducted.
ganglia of the infected person [2] . Due to decreasing VZVspecific T cell-immunity with increasing age, a reactivation of the virus can occur and manifests as shingles (herpes zoster, HZ) [3, 4] . However, other causes (e.g. HIV or psychological stress) can also contribute to reactivation of the virus [5] . HZ is a self-limiting and painful rash that usually affects the skin of the trunk or the head for approximately 4 weeks [6] [7] [8] . About 20-30 % of individuals develop HZ at least once in their lifetime [9] . The main complication of HZ is postherpetic neuralgia (PHN), a longlasting burning and severe pain persisting for months in the affected skin area after the rash has resolved [10, 11] .
In 2006 the European medicine agency (EMA) licensed the first vaccine against HZ and PHN for people 50 years of age and older [12] . This live-attenuated vaccine demonstrated its efficacy in a randomised controlled trial including individuals aged C60 years, reducing HZ and PHN-incidence by 51 and 67 %, respectively [13] . The vaccine's effectiveness was confirmed in a community setting in the US among adults aged 60 years or older [14] . A recent clinical trial determined a vaccine efficacy in preventing HZ in people aged 50-59 years of almost 70 % [15] . Another vaccine candidate is currently being tested in a phase III clinical trial for its efficacy in preventing HZ in the elderly [16] . As of 2012, the licensed vaccine was not yet available on the market in most European countries. But it can be expected that the vaccine will be available on the German market in the near future.
In order to support the evidence-based decision-making process concerning a potential HZ-vaccination recommendation in Germany, we aimed to describe the epidemiology and to estimate the cost of HZ and PHN in the German statutory health insurance (SHI) system.
Methods

The database
In Germany, almost 85 % of the population (69.6 million people; February 2012 [17] ) is covered by the SHI. As of October 2012, there were in total 144 SHIs in Germany that offered equal mandatory services to their members. The database used in this retrospective analysis contained a sample of the SHI ''Allgemeine Ortskrankenkasse'' (AOK) Hesse (one of the 16 federal states in Germany) and data from the Regional Association of SHI-Accredited Physicians (KV) of Hesse [18] . Therefore, this database combines both patient-related billing-data from the SHI and patient-related treatment-documentation from the KV. The combined database covers a population of approximately 240,000 individuals, for which information on age, sex, and details relating to insurance status (e.g. employed, retired, etc.) were included. The following information on services is recorded on a patient-level in the database: treatment details in medical practices (where the outpatient care is organised in Germany), drug prescriptions, diagnoses records, and therapeutic appliance, inpatient treatment, sick-pay, co-payment, and sick-leave. Since the database included all institutions of the healthcare system in Germany, hospital admissions, hospital discharge, and referrals between general practitioners (GPs) and specialists could be tracked for each individual patient. Therefore, a 'patient career' over time and relevant treatment costs could be identified on an individual basis in a cohort fashion. The general utilisation of this database was admitted and approved by the data protection officer of the Ministry of Social Affairs Hesse and the data protection commissaries of AOK Hesse and KV Hesse. Only anonymous data were used for the analysis. Furthermore, German guidelines of good practice for secondary data analysis were followed throughout the analyses [19] .
For the assessment of costs and for the calculation of age-specific incidences, individuals of all ages with a HZ-diagnosis in 2005-2008 were included. To guarantee that only acute cases and costs for the 1st year after disease onset were included, for each individual we considered an observation period of 2 years (i.e. one HZ-diagnosis-free year before diagnosis, and 1 year after HZ-diagnosis). Hence, for cases diagnosed in 2005 we considered the year 2004 to identify and exclude non-acute cases. On the other hand for cases diagnosed in 2008 we considered 2009 to identify all relevant costs up to 12 months after the diagnosis. Therefore, the dataset contained patient data from 2004 to 2009. Costs up to 1 year after HZ diagnosis were considered, because 3 months from HZ-onset are required for the appearance of PHN, and PHN can persist for, on average, 9 months [13, 20] .
Identification of HZ-and PHN-cases
Definition of a HZ-case
In the database, all individuals with a diagnosis code according to the 'International Statistical Classification of Diseases and Related Health Problems'10th Revision (ICD-10) [21] of B02.* or G53.0 between 2005 and 2008 were identified. Due to billing guidelines in the outpatient sector, the physician has to indicate the reliability of the diagnosis, in addition to the ICD-10 code. There are four types of reliability: (1) ''assured''; (2) ''conjectured''; (3) ''status after disease''; and (4) ''disease excluded''. To ensure that all potential HZ-cases are considered, we included HZ-cases with respective ICD-10 codes and ''assured'' or ''conjectured'' as diagnosis reliability [22] . Outpatient diagnoses are documented by physicians for the SHI (for reimbursement purposes) on a quarterly basis. However, for the definition of PHN-cases and for the assessment of illness-related costs, the exact calendar date of HZ-diagnosis (with date of onset) was necessary. Therefore, we defined the calendar date as the date of first HZ-diagnosis based on the earliest date of one of the following conditions (no hierarchical order):
1. Date of prescription of a HZ-specific drug (e.g. virostatics or specific immunoglobulin) ( Table 1) ; or 2. Date of prescription of pain-medication or co-analgetics by a physician who documented the HZ-diagnosis, if there was no prescription of those drugs in the previous quarter less than 4 weeks before the initial prescription in the quarter of HZ-onset ( Cases documented with ICD10-code G53.0 (PHN) but without the HZ code B02.2 (which is not in accordance to billing guidelines for physicians) were regarded as HZcases.
Definition of a PHN-case
In accordance to previously published studies, we defined PHN as pain persisting for at least 3 months after HZ-onset [13, [24] [25] [26] [27] [28] [29] [30] [31] . A HZ-patient became a PHN-case if there was a PHN-diagnosis documentation or the initiation of a PHNrelated pain therapy. Diagnoses with B02.* or G53 ICD-10 codes [21] causing hospitalisation or sick-leave 3-6 months after the date of HZ-diagnosis were considered as a PHN-diagnosis. A PHN-related pain therapy was defined as follows:
1. Absence of a prescription of opioids, antidepressants, or anticonvulsants during the 3 months prior to HZdiagnosis (Table 1) , plus 2. At least one prescription of an agent listed in Table 1 within the 3 months after the HZ-diagnosis, plus 3. A minimum of one prescription of opioids, antidepressants, or anticonvulsants during 90-180 days after HZ-diagnosis (Table 1) .
Perspectives and cost sectors
Costs were analysed from the perspective of the SHI (payer perspective) as well as from the societal perspective (see Table 2 ). The payer perspective comprised costs for outpatient care, drug prescription, therapeutic appliance, and hospital stay. Sick-pay as transfer payments was also included in this perspective. The cost sectors for the societal perspective included all costs of the payer perspective (except for sick-pay), and in addition costs for sick-leave and patient co-payment. We accounted the HZ/PHN-related costs up to 1 year after disease onset. Data for the following cost sectors were regarded:
Sick-pay (transfer payments) According to the German Social Security Code, the SHI covers 70 % of the insured's gross earnings per month after 6 weeks of work absenteeism (for the first 6 weeks the employer continues to pay the salary).
Outpatient treatment The claims form, documented by the consulted physician, comprises the following information: insured's identification number (pseudonymized); quarter and year of diagnosis (ICD-10 code [21] ); physician's identification number (pseudonymized); service codes with date of service. During the study period service codes were reimbursed by allowances and point values. However, the Euro amount of one point is available after respective quarter. Since the KV of Hesse provided this data we were able to connect the service codes to corresponding amount in Euro paid by the SHI for each time period. Hence, we identified the potential costs for HZ and PHN-treatment in the outpatient sector. All physician groups (GP and all medical specialist groups, e.g. dermatologists and ophthalmologists) were considered. How we estimated the effective treatment costs of HZ and PHN will be described in the ''Cost-estimation: direct diagnosis-linkage and control-group design'' section.
Drug prescription Each drug on a prescription can be identified by its national unique central pharmaceutical number (PZN). We linked it to the nationwide uniform pharmacy retail price (PRP) for 2010 or the drug-related reference price. Table 1 presents the drugs we considered in accordance with existing treatment guidelines in Germany as relevant for the treatment of HZ and PHN [23] .
Therapeutic appliance We considered transcutaneous electrical nerve stimulation (TENS) devices and low-frequency electrical stimulation devices as relevant for pain treatment in HZ/PHN-management.
Inpatient treatment From the database we used the insured-related information concerning length of hospital stay and main diagnosis. Since 2004 hospitals receive from SHI an allowance based on German Diagnosis Related Groups (G-DRG) depending on patient's age, sex and diagnosis [32] . Costs due to HZ/PHN-related hospitalization were assessed by linking the main diagnosis (reason for hospital stay) to the corresponding G-DRG and therefore to the respective Euro amount.
Sick-leave For cost calculation, the human capital approach (HCA) was applied [33] . We identified HZ/PHNrelated sick-leave from ICD-10 codes [21] documented on the available sick-leave certificates together with information on duration of sick-leave. Since in German claims data more than one ICD-10 diagnosis can be documented per one sick-leave episode, we included only those sick-leave episodes issued by the GP who documented the HZ/PHN-diagnosis in the quarter that covers the beginning date of that sick-leave episode. Furthermore, we identified sick-leave entitled individuals by their insurance status. Sick-leave entitled individuals were employed, job seeking, voluntary insured, and individuals in rehabilitation. We used the monthly employer's labor-costs (employee's monthly gross earnings plus employer's contribution of social insurance premium per employee, which is about 28 % [34] of the employer's monthly gross earnings) on age and sex in Germany broken down on a daily basis [33, 35] . These amounts were computed with the number of sick-leave days per patient. In order to estimate the costs conservatively, we utilized data from the Federal Statistics Office of Germany [36] , which considered both, full-time and part-time employment mean gross earnings.
Co-payment According to the German Social Security Code for insurance from the age of 18, the following copayments were considered in this study: outpatient contact allowance per quarter (€10), co-payment for certain drugs (Table 1) , and therapeutic appliance (10 % of price, minimum €5 and maximum €10, never more than the price itself). Besides drug co-payment, payers reimburse certain drugs until the reference price only. The difference between reference price and the PRP has to be paid by the insured person in addition to co-payments. Furthermore, an allowance per hospital day was considered, which is €10 per day and has to be paid up to a maximum of 28 days in hospital.
Cost-estimation: direct diagnosis-linkage and controlgroup design Inpatient treatment, sick-pay, sick-leave, and certain parts of co-payment were services with a direct diagnosis-linkage to HZ and PHN-treatment (Table 2) . However, not all drug prescriptions (e.g. pain-medication), outpatient procedures (e.g. general counseling), therapeutic appliance (e.g. TENS devices), and co-payments (outpatient contact allowance per quarter) are exclusively HZ/PHN-specific. In order to estimate HZ/PHN-costs accurately, we performed a control-group design. Controls were selected and assigned individually to cases based on the following matching-variables: age, sex, treatment costs in the year before the case was diagnosed with HZ, and sick-leave entitlement. We considered for every case one control for each service sector without direct diagnosislinkage. The difference between treatment costs of the case and the control within the year after the HZ-diagnosis was regarded as the relevant treatment costs due to HZ/PHN. In order to separate PHN-specific costs, we computed the differences between mean costs of HZ-cases with PHN and mean costs of HZ-cases without PHN, matched according to age group, sex and sick-leave entitlement.
Statistics and software
When considering individual cost sectors, we calculated mean costs per user of the specific service (Table 3 ). In the section 'total annual costs' we computed average HZ-and PHN-costs based on all HZ/PHN-cases independent from individual utilisation (Tables 4, 5 ). To estimate total annual costs for HZ-and PHN-treatment in the SHI-population, we computed the number of cases in the SHI-population with the average costs per case and age-group from both perspectives. Total as well as stratum-specific incidences were estimated along with 95 % confidence-intervals (95 % CI). Costs per case were calculated along with bias-corrected and accelerated (BCA) intervals (95 % CI) using bootstrapping (2,000 replicates) [37] . To allow extrapolation of the results from the regional SHI to the total SHI-population in Germany, all incidence and cost figures were standardised according to age and sex of the SHI-population in Germany (reference date: 31 July 2010) [38] . We inflated all monetary amounts to 2010 Euros by using inflation rates from the German Federal Office for Statistics [33, 39] .
To allow better comparison with studies from other countries, we calculated the cost findings from other countries inflated to 2010 amounts within each study's country and converted these respective amounts via the gross domestic product purchasing power parity (GDP PPP) into Euros (Germany as reference country) according to Welte et al. [40] based on data from the Organization for Economic Co-operation and Development (OECD) [41] . (Tables 4,  5 ). Figure 1 presents the incidence of HZ and the proportion of PHN among HZ-cases by age group. In 24 % of cases the PHN ICD-code G53.0 was documented without HZ-code B02.2.
Proportion of HZ-cases developing PHN
We identified 301 PHN-cases in our database. All PHNcases were over 30 years of age and 278 of them were at least 50 years old. These figures resulted in a mean proportion of 4. (Tables 4, 5 ). Similar to the HZ incidence, the proportion of HZ-cases developing PHN increased with age ( Fig. 1) : Among HZ-cases aged C50 years, 6.0 % (95 % CI 5.3-6.7) developed PHN, which resulted in the fact that 90 % of all PHN-cases can be found in this age group (Tables 4, 5 ).
Costs of illness
Utilization and costs per user
For all cost sectors, Table 3 provides an overview of the utilization of services and the mean costs per user for 1 year following disease onset. The results of the utilization and cost analyses are presented separately for costs related to HZ (HZ) and PHN-related costs (PHN). As presented in Table 3 , the proportion of users and respective costs varied between the sectors of care and between HZ and PHN. In brief:
Sick-pay A low proportion of HZ-cases required sick-pay (Table 3) . HZ-cases younger than 30 years did not experience sick-pay. Sick-pay figures became more than tenfold higher when considering PHN.
Outpatient Almost 100 % of HZ-cases had at least one outpatient physician contact; among these about 90 % had contact to a GP. All PHN-cases utilised outpatient treatment.
Drug prescription About 83 % of HZ-cases and 100 % of PHN-cases had drug prescriptions. While 90 % of individuals over 50 years of age received drugs, only 45 % of the under-20-year-old HZ-cases did.
Therapeutic appliance With about 1 % among HZ-cases and 3 % among PHN-cases, this treatment option was applied only infrequently in HZ/PHN management.
Inpatient The proportion of HZ-related hospitalisation increased from 0.8 % in the youngest age group (0-9 years) to about 5 % in the oldest individuals (80 years and older). These figures resulted in hospitalisation rates of 2.8 % of all HZ-cases and 3.2 % of HZ-cases 50 years and older, respectively. On average, an inpatient HZ-case spent 9.4 days in hospital. Mean duration of hospitalisation was associated with age and ranged from 4 days in individuals aged \10 years to about 12 days in patients 80 years and older (P \ 0.001). The hospitalisation rate among PHNcases was about five-fold higher compared to the rate of HZ-cases. Co-payment Of all HZ-cases, 90 % had to make copayments. In patient 50 years and older, 96 % had to cofinance services or treatments out of pocket. However, the average amount was below €13 for HZ-cases and below €39 for PHN-cases (Table 3) .
Total annual costs
Total annual HZ-related and PHN-related costs per case and the total costs extrapolated for the SHI are presented in Table 4 (payer perspective) and Table 5 (societal  perspective) . From the payer perspective, one HZ-case cost €210 (95 % CI 190-230) for HZ treatment on average (Table 4) . In addition to HZ-specific costs one PHN-case generated PHN-related costs of €1,123 (95 % CI 831-1,525). Based on these results, we estimated that, in 2010, the SHI system in Germany was faced with a total bill of €85 million for HZ treatment and an additional €20 million for PHN treatment, resulting in a total of €105 million (Table 4) . Costs per HZ-case increased slightly with age. As a result, and due to the higher number of cases in this age-group, most of the total costs were incurred by persons aged 50 years and older. PHN-related costs per case were higher in middle-aged individuals. Total PHN-related costs did not show a trend by age group. From the societal perspective, one HZ-case cost €376 (95 % CI 350-403) for HZ-treatment on average (Table 5 ). In addition to the HZ-specific costs, each PHN-case generated PHN-related costs of €1,645 (95 % CI 1,213-2,247). When considering the societal perspective (all costs except transfer payments) based on SHI-population figures, total costs were €182 million (?73 %) ( Table 5 ). HZ-related as well as PHN-related costs per case were higher in workingaged individuals than in the elderly. Despite lower incidence rates, the total costs for HZ and PHN-treatment were highest in individuals aged between 40 and 59 (€74 million as compared to €57 million in the age group 60-79 or €26 million in the age group 20-39 years), due to the cost of sick-leave.
Discussion
By utilizing a combined dataset that contained both patientrelated billing-data from one large regional SHI and patient-related treatment-documentation from one regional association of SHI-accredited physicians, we were able to describe the epidemiology of HZ and PHN and to estimate the costs related to the disease in the SHI system in Germany. With more than 400,000 incident HZ-cases annually and average costs of €210 per HZ-case, and an additional €1,123 per HZ-case that developed PHN, the 1st treatment year of incident patients poses a considerable clinical and economic burden to the SHI system in Germany.
In our study population, two-thirds of HZ-cases were 50 years of age and older. The observed incidence for people aged C50 years lies within the range of other studies in Germany that assessed HZ incidence in this age group (3.4-9.6 per 1,000 PY) [22, 42, 43] . The overall incidence of 5.8 HZ-cases per 1,000 PY for the total population is also compatible with the magnitude reported in studies from other European countries, which ranges between 3.8 and 7.9 cases per 1,000 PY [9, 25, 26, [44] [45] [46] [47] . For the US and Canada, HZ incidences were reported in a range between 1.7 and 3.23 HZ-cases per 1,000 PY [48] [49] [50] [51] . Table 4 Estimation of total annual costs due to HZ and PHN in the statutory health insurance (SHI) population in Germany-payer perspective Based on the common definition of PHN (pain persisting at least 3 months after HZ-rash onset [13, [24] [25] [26] [27] [28] [29] [30] [31] ), 4.5 % (6.0 % in people 50 years and older) of HZ-cases in our study population developed PHN. Depending on the age groups considered in other studies, the proportion of HZ patients developing PHN in the US [3, 51, 52] , the UK [25] , Germany [43] , France [26] , Spain [46] , the Netherlands [28] , Australia [53] , and Italy [44] ranged between 2.6 and 14.5 %.
In our population, 2.6 % (3.1 % in individuals 50 years and older) of HZ/PHN patients were in hospital for an average duration of 10 days. Schiffner-Rohe et al. [54] found a HZ related hospitalisation rate in Germany of 3.4 % for HZ patients 50 years and over. The proportion of patients with HZ being hospitalised ranged between 1.3 and 3 % in countries like France [26] , the UK [9] , the US [51] , Australia [53] , and Italy [44] . The average length of HZ patients being hospitalised was 7.8-14 days in France [26] , Italy [44] , and Australia [53, 55] .
When comparing our cost estimates to findings from a study applying a similar database that consisted of data from the SHI and KV in Hesse in 2004 and the target population 50 years and older, we found lower costs per HZ-case [54] . This is due mainly to a lower proportion of HZ patients being hospitalised, shorter length of hospital stay, lower costs for sick-leave due to HZ, and due to methodological differences, e.g. range of included pain drugs and differences in cost assessment.
Our costs for an average HZ-case from the payer perspective are, at €210, at the lower range of results of other industrialised countries such as the UK (PPP €190) [56] , Spain (PPP €289) [46] , or the US (PPP €592) [57] . In contrast, when considering costs from the payer perspective for HZ-cases in the elderly, our estimated costs are more than twice as high as estimates from the UK (PPP €93) [25] . Also the average costs per PHN-patient is, in our study population, more than 30 % higher than in Spain (PPP €767) [46] . By adapting all results to one equal level in terms of reference year (inflation) and GDP PPP in Euros, the residual differences might be derived from, among other factors, different prices, treatment procedures, and study designs.
The utilisation of the AOK Hesse/KV Hesse database may, however, have some limitations. First, our data-base covers one region and one health insurance fund. Patients insured with the AOK in Hesse may not necessarily be representative of the German SHI population in general since some differences in social structure and morbidity among insurances exist [58, 59] . Especially the findings concerning sick-leave data may not necessarily be representative of the total German SHI population, since the insurance population developed historically and differences in the structure of employment exist [60] . Our figures Table 5 Estimation of total annual costs due to HZ and PHN in the SHI population in Germany-societal perspective [61] . And since sick-leave certificates may contain more than one ICD-10 diagnose per sick-leave episode, an exact diagnosis linkage with HZ/PHN was sometimes difficult. However, since we included HZ/PHN sick-leave certificates only if they were documented by the GP who diagnosed HZ or PHN in the respective individual, we were able to minimise inaccuracies in sick-leave estimates. Furthermore, care pathways for HZ/PHN-patients may vary between regions in Germany. However, since equal services and prices are mandatory for all SHIs in Germany, countrywide treatment guidelines for HZ and PHN exist, and there are no substantial differences in the disease epidemiology compared to a HZ incidence study covering almost the whole SHI in Germany [22] , we believe that an extrapolation of our study results to the total SHI population in Germany (i.e. 90 % of the total population in Germany) is justified.
Second, we found a certain miscoding in the database: in a significant proportion, the PHN ICD-code was documented without a HZ-code, even though billing guidelines specifically ask for it. This miscoding might be derived from the lack of a uniform definition of PHN. Due to this partially inaccurate use of ICD-10 code for PHN, we were not able to identify all PHN-cases in the outpatient sector by diagnosis, but this under-detection was corrected via case-identification through treatment documentation as described in the Methods section. Since we had to perform both a control-group design and a PHN-cost separation step to estimate HZ/PHN-related costs, the estimated costs might differ slightly from reality.
Third, a slight overestimation might be derived from prices for drugs, reimbursed by payer (SHI). As we considered pharmacy retail prices from public registers, we could not consider the actual prices paid by a SHI. Since the SHI negotiate prices for (generic) drugs with manufacturers confidentially, the real prices of the drugs considered in this study might be lower.
Fourth, a proposal for health economic evaluations in Germany suggested that, for the estimation of inpatient costs, capital costs per inpatient day (accounting to the societal perspective) should also be considered in addition to G-DRGs [62] . However, since actual data to account for these costs are lacking, we decided to neglect this cost factor. This might lead to an underestimation from a societal perspective.
Fifth, taking sick-pay into account has to be discussed critically. However, we considered costs for sick-pay as transfer payments, as done by Greiner [63] and Luce et al. [64] , and ascribed them to the payer perspective only [33] . Since sick-pay in HZ/PHN in Germany on average seems to occur only seldomly, these costs only minimally affected costs from the payer perspective.
Finally, we were unable to estimate costs for privately paid therapy (e.g. over-the-counter drugs, acupuncture, or homeopathic treatments) from our database. Because this might be an important therapy option among HZ/PHNpatients, costs from the societal perspective might be even higher than estimated from our database. Nevertheless, the most relevant medications in HZ/PHN-therapy were considered in our study and therefore the results presented give a valid estimate for the magnitude of the costs related to HZ and PHN in Germany.
Besides these limitations, this study holds several significant benefits. The analysis is based on a sample of over 240,000 individuals of all ages. Due to the detailed drug prescription information in the database we were able to use, in addition to diagnosis-related codes, a prescriptionapproach to identify potential PHN-cases. Hence, we compensated the partially incorrect PHN diagnosis coding. Furthermore, this database, with its combination of SHI accounting data and patient treatment information, allowed Hence, annual volatility in costs caused by political reform intervention or other causes could be counteracted. Therefore, these findings provide very detailed input data for upcoming health economic evaluations of HZ vaccination, which will inform future decision-making processes regarding a potential HZ vaccination recommendation in Germany.
Conclusion
Our findings illustrate the epidemiological and economic impact of HZ and PHN, which affect mainly individuals above 50 years of age, in the German healthcare system. Due to the aging population in Germany, it can be expected that the annual number of cases will increase in the future and therefore also the total costs for the healthcare system and society. HZ-and PHN-related costs per case and total costs from the payer perspective varied by age group but without showing a clear trend. From the societal perspective, costs per case and total costs were highest in the working-age population due to costs for sick-leave. These age-specific differences in costs need to be taken into account in future analyses when assessing the cost-effectiveness of the vaccination against HZ and PHN.
